Pharma Industry News

BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study

Breyanzi demonstrated a statistically significant improvement in event-free survival compared to standard of care

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]